TeamDrive
RUS

Company

Team Drive was founded in 2011 as the brainchild of two of Russia’s most successful and prominent business leaders, Leonid Melamed (ex-CEO of Sistema JSFC*, Russia’s largest publically traded holding, and previously CEO of Rosno, Russia’s largest insurer and MTS, Russia’s largest telecommunications operator) and Vladimir Gurdus (ex-CEO of Medsi, Russia’s largest private healthcare provider). 

Having spent two decades successfully conceiving, building, operating and exiting  multi-billion-dollar brands and businesses in Russia and the CIS, Leonid and Vladimir came to the conclusion that not only could Russian assets and businesses be created that were highly competitive in Russia, but highly competitive at global scale, with concomitant returns to equity. In other words, that Russian assets, capital, talent, ideas, companies and brands represent a vast and largely untapped reservoir of investor and customer value potential, both in a Russian market context as well as in a global market context. Team Drive was created specifically to unlock this untapped value potential.

We offer an end-to-end asset management and value augmentation service in Russia with a focus on distressed or underperforming assets going all the way from initial control, creditor/investor alignment, goals/objectives definition, detailed brand and market differentiation strategy to business planning, operational execution and optimal exit, operating to global best practices. 


*Sistema JSFC is the largest publicly-traded diversified holding company in Russia and the CIS. Incorporated in 1993, Sistema is now one of Russia's top ten companies by revenues and is one of the largest investment companies in the world. The group owns a diverse set of public and private companies, which it holds in two distinct portfolios.

Media Center

  • 23 October 2018

    Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients

    Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in optimizing treatment for patients with various stages of breast and prostate cancer. The findings, presented at the ESMO 2018 Congress in Munich, Germany, demonstrated that the Oncotype DX tests identify patients who will or will not benefit from a specific treatment.

  • 23 October 2018

    Russian cancer drug based on smallpox vaccine undergoes preclinical studies

    Siberian scientists have brought to the final stage of preclinical testing the only Russian therapeutic cancer drug. This part of the study is expected to be completed by the end of 2019, according to Sergei Netesov, Chairman of the Board of the Association for the Development of the Innovative Territorial Cluster of the Novosibirsk Region in the Sphere of Biopharmaceutical Technologies (‘Biopharm’).

  • 22 October 2018

    Pfizer preps for BMS showdown with Bavencio kidney cancer combo data

    Pfizer has long been a player in kidney cancer, but it’s looking to take things up a notch—and challenge next-gen rival Bristol-Myers Squibb—with its latest data. Sunday at the European Society for Medical Oncology annual meeting, the New York drugmaker and partner Merck KGaA said their immuno-oncology agent Bavencio, in tandem with Pfizer’s Inlyta, had staved off cancer progression in previously untreated patients by a median 13.8 months, compared with 8.4 months for standard-of-care Sutent, another Pfizer drug.

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

Read more